PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Gold-standard clinical trials fail to capture how behavior changes influence treatment

Gold-standard clinical trials fail to capture how behavior changes influence treatment
2015-06-10
(Press-News.org) PRINCETON, N.J.--Double-blind clinical trials for new drugs are considered the "gold standard" of medical research because they're designed to determine the efficacy of a treatment free from doctor and participant bias.

But one effect these trials fail to measure is how a medication's performance can vary based on patients' lifestyle choices, especially if patients change their habits because they are anticipating treatment, according to a new study published in PLOS ONE.

A recent meta-analysis of six clinical trials, led by researchers from Princeton University, the California Institute of Technology and Cambridge University, shows that people who felt confident that they received the drug changed their behaviors in ways that not only improved their health outcomes but also made the drug itself more effective. They also were less likely to bow out of a clinical trial.

The researchers propose a new trial design - which they call a two-by-two blind trial - that can measure such interactions between behavior and treatment. Unlike current double-blind clinical trials, the new model works by randomizing not only the treatment status of patients but also the probability with which they receive treatment. This helps determine how behavioral changes, such as changes in diet and exercise, influence treatment outcomes.

"Our proposed design has the potential to better evaluate the effectiveness of treatments targeting conditions related to mental health, substance abuse and smoking cessation, in which behavior is known to play an important role," said co-lead author Sylvain Chassang, a professor of economics and public affairs at Princeton's Woodrow Wilson School of Public and International Affairs.

In current double-blind randomized controlled trials (DBRCT), participants are either placed in a treatment group, in which they try out a new drug, or they remain in the control group and keep their current medications. Participants do not know which group they are in, but before the trial begins, all participants are told the odds of their being placed in either the treatment or control group (a 50/50 percent chance in most cases).

But not all patients behave the same during a trial, and behavior might affect the overall effectiveness of a particular drug. This is what led Chassang and his collaborators - Erik Snowberg from Caltech, Ben Seymour from Cambridge University and Caley Bowles from Harvard University - to study whether the likelihood of receiving a new treatment changes the overall effectiveness of a drug.

"Most medical research just wants to know whether a drug will work. We wanted to go a step further and design new trials that would take into account the way people behave. We naturally turned to the mathematical tools of social science to do this," Snowberg said.

The researchers propose a new clinical trial design that varies the probability of treatment across participant groups. Instead of having a 50/50 chance of receiving treatment, participants are placed in high- and low-probability treatment groups. In the high-probability group, there is a 70 percent chance of receiving treatment while the low-probability group would have only a 30 percent chance of receiving treatment. Following current guidelines, all participants are made aware of their likelihood of receiving the new treatment.

"Likelihood of treatment has an important impact on behavior," Chassang said. "If my odds of being treated are low, then my incentives to try and change my behavior are also low. If my odds of being treated are higher, then my incentives to change my behavior are also higher. We wanted to measure how these behaviors played a role in the overall effectiveness of a drug."

"It's a very small change to the design of the trial, but it's important," Snowberg said. "The effect of a treatment has these two constituent parts: pure treatment effect and the treatment-behavior interaction. Standard blind trials just randomize the likelihood of treatment, but if you want to separate out the pure treatment effects and the treatment-behavior interaction effect, then you have to randomize both the treatment and the behavior."

To test their hypothesis that treatment and behavior interact, the researchers conducted a meta-analysis of data from six clinical trials involving two antidepressants, paroxetine and tricyclic imipramine. By changing the variation in the likelihood of treatment across trials, they were able to determine how much of the overall effect is attributable to behavior change alone (also known as a "placebo effect"), the treatment alone and the interaction between the treatment and behavior.

First, the researchers evaluated whether participants behaved differently based on whether they had a high or low probability of receiving the treatment. They found that in trials where participants had a high probability of treatment, around 70 percent, the dropout rate was significantly lower than in trials with participants who had a lower probability of treatment, around 50 percent.

They then wanted to evaluate how behavior affected treatment outcomes. In the case of paroxetine, they found that the effectiveness of treatment increased with the likelihood of being treated. This change, the researchers argue, can be interpreted as an interaction effect between drugs and changes in behavior. While specific patient behaviors were not directly observable, the analysis shows that participants who feel confident about receiving treatment change their behavior in a way that makes the drug more effective.

"Here is one way to make sense of this data," Chassang said. "Imagine that an antidepressant that works by reducing social anxiety and only delivers results if participants are more socially active. If participants who are more optimistic about receiving treatment are also more likely to attend parties and gatherings, then the effectiveness of the drug will vary with likelihood of treatment."

"Normally what you get when you run a standard blind trial is some sort of mishmash of the treatment effect and the treatment-behavior interaction effect. But knowing the full interaction effect is important. Our work indicates that clinical trials underestimate the efficacy of a drug whenever there are complementarities between drugs and changes in behavior," Snowberg said. "It may be the case that the 50 percent probability isn't high enough for people to change any of their behaviors, especially if it's a really uncertain new treatment. Then it's just going to look like that drug doesn't work, and that isn't the case."

The researchers note that the magnitude of interaction effects may vary across drugs. In the case of tricyclic imipramine, they found no such interaction effects between treatment and behavior.

"The idea that experiments should take into account how behavior affects the effectiveness of treatments has applications in a number of fields," Chassang said. "This includes agriculture, public health and education. This model is really applicable in any experiment in which participant motivation is an important determinant of outcomes."

INFORMATION:

This study was supported by the National Science Foundation (grant no. SES-1156154). The paper, "Accounting for Behavior in Treatment Effects: New Applications for Blind Trials," will be published June 10 in PLOS ONE.


[Attachments] See images for this press release:
Gold-standard clinical trials fail to capture how behavior changes influence treatment

ELSE PRESS RELEASES FROM THIS DATE:

Plants may run out of time to grow under ongoing climate change

2015-06-10
A key potential 'benefit' of global warming--namely, that plants at northern latitudes will thrive in a warmer world--is challenged by a new study released by University of Hawai'i scientists today. The prevailing assumption ignores the fact that plants in the North will remain limited by solar radiation, curbing positive effects of warming and additional CO2 availability. In addition, that same warming could surpass plant temperature tolerances in tropical areas around the world, and further be accompanied by drought. "Those that think climate change will benefit plants ...

Risk for sleep disorders among college freshmen may predict retention, success

2015-06-10
DARIEN, Ill. -- A new study suggests that the risk for sleep disorders among college freshmen may be a predictor of retention and academic success. Results show that students at risk for a sleep disorder were more likely to leave the institution over the three-year period, although this association was weakened when covariates were included. Risk for sleep disorder also predicted grade point average (GPA) at the end of the first and second years. 'A survey that screens for sleep disorders administered when students first enter college may identify a potentially modifiable ...

Clinical trial launched to assess safety and efficacy of autism drug treatment

2015-06-10
Researchers at the University of California, San Diego School of Medicine have launched a clinical trial to investigate the safety and efficacy of an unprecedented drug therapy for autism. The phase 1 clinical trial, which is recruiting 20 qualifying participants, will evaluate suramin -- a century-old drug still used for African sleeping sickness -- as a novel treatment for children with a diagnosis of Autism Spectrum Disorder (ASD). Previous published research by Robert K. Naviaux, M.D., Ph.D., professor of medicine, pediatrics and pathology at UC San Diego School of ...

Fragile X proteins involved in proper neuron development

2015-06-10
MADISON, Wis. -- Fragile X syndrome is the most common inherited intellectual disability and the greatest single genetic contributor to autism. Unlocking the mechanisms behind fragile X could make important revelations about the brain. In a new study published June 4 in the journal Cell Reports, researchers from the University of Wisconsin-Madison Waisman Center and Department of Neuroscience show that two proteins implicated in fragile X play a crucial role in the proper development of neurons in mice. They also show that while the two proteins act through distinct mechanisms ...

Obesity linked to adrenal disorder in teens may increase risk for cardiovascular disease

2015-06-10
Researchers at Children's Hospital Los Angeles have demonstrated that adolescents and young adults with congenital adrenal hyperplasia (CAH) have significantly increased amounts of abdominal fat tissue, placing them at greater risk for harmful conditions linked to obesity, including cardiovascular disease (CVD). Their study, which reveals new information about the role of abdominal fat in patients with CAH and points to a need for targeted prevention and therapeutics to avoid these adverse effects, will be published online June 10, 2015 by The Journal of Clinical Endocrinology ...

Cutting-edge research unveiled at 2015 AAPS National Biotechnology Conference

2015-06-10
SAN FRANCISCO - Innovative vaccine and tumor research will be unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference (NBC). The meeting takes place Monday, June 8- Wednesday, June 10 at the San Francisco Marriott Marquis. This year's conference is organized into five meeting workstreams: Chemistry, Manufacturing, and Controls (CMC) including Formulation, Characterization, Stability and Biomanufacturing; Research and Discovery; Clinical Pharmacology, Pharmacokinetic/Pharmacodynamic (PK/PD), and Bioanalytics; Regulatory; ...

When modern Eurasia was born

When modern Eurasia was born
2015-06-10
Was it a massive migration? Or was it rather a slow and persistent seeping of people, items and ideas that laid the foundation for the demographic map of Europe and Central Asia that we see today? The Bronze Age (about 5,000 - 3,000 years ago) was a period with large cultural upheavals. But just how these upheavals came to be have remained shrouded in mystery. Assistant Professor Morten Allentoft from the Centre for GeoGenetics at the Natural History Museum of Denmark at the University of Copenhagen is a geneticist and is first author on the paper in Nature. He says: - ...

Ice sheet collapse triggered ancient sea level peak: ANU media release

Ice sheet collapse triggered ancient sea level peak: ANU media release
2015-06-10
An international team of scientists has found a dramatic ice sheet collapse at the end of the ice age before last caused widespread climate changes and led to a peak in the sea level well above its present height. The team found the events 135,000 years ago caused the planet to warm in a different way to the end of the most recent ice age about 20,000 to 10,000 years ago. The findings will help scientists understand the processes that control Earth's dramatic climate changes, said the leader of the study, Dr Gianluca Marino of The Australian National University (ANU). "We ...

Single protein causes Parkinson's disease and multiple system atrophy

2015-06-10
Several neurodegenerative disorders are caused by aggregates of a single protein known as alpha-synuclein. In collaboration with CNRS and the University of Antwerp, KU Leuven neurobiologists have discovered that the shape of these aggregates - 'cylinders' or 'ribbons' - determines whether a patient develops Parkinson's disease or Multiple System Atrophy, respectively. Typical of neurodegenerative disorders is the disrupted communication between brain cells together with a loss of cells in specific brain regions. For some brain diseases this phenomenon is linked to a ...

All change for bacterial outer membrane proteins

2015-06-10
The discovery of how a group of bacteria rapidly adapts to changing growth conditions could have implications for future antibiotic development, according to research at the University of Oxford and the University of York. Led by Professor Colin Kleanthous at Oxford and Dr Christoph Baumann at York, the research which also involved key collaborators Mark Sansom at Oxford and Jacob Piehler at the University of Osnabrück, is published in Nature. Gram-negative bacteria are a major cause of disease, in part because they have a robust outer membrane that protects ...

LAST 30 PRESS RELEASES:

New strategies to enhance chiral optical signals unveiled

Cambridge research uncovers powerful virtual reality treatment for speech anxiety

2025 Gut Microbiota for Health World Summit to spotlight groundbreaking research

International survey finds that support for climate interventions is tied to being hopeful and worried about climate change

Cambridge scientist launches free VR platform that eliminates the fear of public speaking

Open-Source AI matches top proprietary model in solving tough medical cases

Good fences make good neighbors (with carnivores)

NRG Oncology trial supports radiotherapy alone following radical hysterectomy should remain the standard of care for early-stage, intermediate-risk cervical cancer

Introducing our new cohort of AGA Future Leaders

Sharks are dying at alarming rates, mostly due to fishing. Retention bans may help

Engineering excellence: Engineers with ONR ties elected to renowned scientific academy

New CRISPR-based diagnostic test detects pathogens in blood without amplification

Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer

Growing solar: Optimizing agrivoltaic systems for crops and clean energy

Scientists discover how to reactivate cancer’s molecular “kill switch”

YouTube influencers: gaming’s best friend or worst enemy?

uOttawa scientists use light to unlock secret of atoms

NJIT mathematician to help map Earth's last frontier with Navy grant

NASA atmospheric wave-studying mission releases data from first 3,000 orbits

‘Microlightning’ in water droplets may have sparked life on Earth

Smoke from wildland-urban interface fires more deadly than remote wildfires

What’s your body really worth? New AI model reveals your true biological age from 5 drops of blood

Protein accidentally lassos itself, helping explain unusual refolding behavior

With bird flu in raw milk, many in U.S. still do not know risks of consuming it

University of Minnesota research team awarded $3.8 million grant to develop cell therapy to combat Alzheimer’s disease

UConn uncovers new clue on what is leading to neurodegenerative diseases like Alzheimer’s and ALS

Resuscitation in out-of-hospital cardiac arrest – it’s how quickly it is done, rather than who does it

A closer look at biomolecular ‘silly putty’

Oxytocin system of breastfeeding affected in mothers with postnatal depression

Liquid metal-enabled synergetic cooling and charging: a leap forward for electric vehicles

[Press-News.org] Gold-standard clinical trials fail to capture how behavior changes influence treatment